In the heart of Quebec City, Aramis Biotechnologies is pioneering a new frontier in vaccine development. Emerging from the ashes of Medicago, and fortified by decades of research, the company is reimagining how the world produces vaccines—using plants instead of eggs or cell cultures. Their vision: a scalable, flexible, and eco-friendly biomanufacturing platform that could not only reshape pandemic preparedness, but also support innovations in fields as diverse as cosmetics, food, and cell-cultured meat.